BNP Paribas’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
Other funds holding REGN
BNP Paribas's REGN Position: Q3 2026 in Review
BNP Paribas reduced its Regeneron Pharmaceuticals (REGN) stake by 1.2% in Q3 2026, selling an estimated $8.31K and leaving 936 shares worth $710K. The position accounts for 0.02% of the portfolio, ranked #184.
BNP Paribas first reported a position in REGN in Q1 2024 and has held it in 11 quarters since. The position peaked at $1.82M in Q3 2024. 1,433 funds tracked by Wall St. Rank hold REGN as of Q3 2026.
- BNP Paribas held 936 shares of Regeneron Pharmaceuticals worth $710K as of Q3 2026.
- BNP Paribas sold 11 Regeneron Pharmaceuticals shares in Q3 2026, an estimated $8.31K.
- Regeneron Pharmaceuticals made up 0.02% of BNP Paribas's portfolio in Q3 2026, its #184 holding.
- BNP Paribas first reported a position in Regeneron Pharmaceuticals in Q1 2024 and has held it in 11 quarters since.
- BNP Paribas's Regeneron Pharmaceuticals position peaked at $1.82M in Q3 2024.
- 1,433 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2026.
Based on BNP Paribas's 13F filing for Q3 2026, filed 12 Nov 2026.